Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Share-based compensation expense

Asset impairment and restructuring costs

Expected credit losses on financial assets and related charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Canopy Growth

Canopy Growth Corp. engages in the production and sale of medical cannabis. The firm operates through the following segments: Global Cannabis and Other Consumer Products. The Global Cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Other Consumer Products segment encompasses the production, distribution and sale of consumer products by Storz & Bickel, This Works, BioSteel, and other ancillary revenue sources. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The firm operates through the following segments: Canada Cannabis, Rest-of-world Cannabis, Storz and Bickel, BioSteel, This Works, and Other. The Canada Cannabis segment includes the production, distribution, and sale of cannabis, hemp, and cannabis products in Canada. The Rest-of-world Cannabis segment focuses on production and sale of cannabis, hemp, and cannabis products internationally. The Storz and Bickel segment produces and sells vaporizers. The BioSteel segment refers to the sale of consumer packaged goods including sports nutrition beverages, hydration mixes, proteins, and other specialty nutrition products. The This Works segment includes the production and sale of beauty, skincare, wellness, and sleep products, some of which have been blended with hemp-derived CBD isolate. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

Canopy Growth Corporation‘s CGC strategy for capturing the U.S. cannabis market was the focal point of a recent fireside chat hosted by Zuanic & Associates . CEO David Klein and CFO Judy Hong provided insights into Canopy USA's (CUSA) growth strategy, financial projections and its significance for investors navigating the evolving cannabis industry.

The U.S. Cannabis Strategy No One's Talking About: Inside Canopy's $300M Plan

Canopy Growth brings the best of California's award winning Claybourne Pre-Roll Joint brand to adult-use consumers across Canada with the launch of 'Frosted Flyers' SMITHS FALLS, ON , Nov. 20, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today through an exclusive licensing agreement the launch of the award-winning California grown Claybourne brand in Canada. This initial launch brings Claybourne's Frosted Flyers Infused Pre-Rolls to Canadian medical and adult-use consumers in five distinct offerings, Blue Dream, Strawberry Cough, Pineapple Express, Grape Gasolina and Banana OG.

Canopy Growth Launches Claybourne Infused Pre-Rolls in Canada

Tilray Brands

Village Farms International

The cannabis industry continues to gain momentum in North America, with Canadian cannabis companies at the forefront of global expansion. As of 2023, the U.S. cannabis industry is projected to surpass $40 billion in annual sales by 2025. This rapid growth reflects increasing legalization efforts and rising consumer acceptance of cannabis products. Recently, discussions around U.S. federal cannabis reform have resurfaced, sparking optimism among investors. These developments could unlock significant opportunities for Canadian companies with existing U.S. partnerships. However, navigating the cannabis market requires strategic planning. Using technical analysis to identify entry points and implementing proper risk management is essential for success.

The Top Canadian Cannabis Stocks for November 2024 Growth

Aurora Cannabis

Cronos Group

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

AdvisorShares Pure US Cannabis ETF

Trulieve Cannabis Corp.

If controversial Republican Matt Gaetz manages to win confirmation as attorney general, his tenure at the Justice Department is expected to be positive for the cannabis industry.

Gaetz as Trump's AG seen as bullish for pot stocks, but confirmation looks unlikely

Zacks.com users have recently been watching Canopy Growth (CGC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Canopy Growth Corporation (CGC) Is a Trending Stock: Facts to Know Before Betting on It

This story came out today about Trump's potential policy on cannabis.  The statement by Chris Christie: When I was asked about the election, I talked about 3 commonalities among both candidates.

Did Cannabis Stocks Finally Bottom?

A reality check around regulatory challenges facing the cannabis sector has taken hold among some of the leading financiers in the industry, as optimism around the promise of a legal market has faded.

Cannabis stock valuations and investments hobbled by regulatory uncertainties, experts say

Canopy Growth Corporation (CGC) Q2 2025 Earnings Call Transcript

Canopy Growth Corporation (CGC) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $1.80 per share a year ago.

Canopy Growth Corporation (CGC) Reports Q2 Loss, Misses Revenue Estimates

Storz & Bickel net revenue increased 32% year-over-year in Q2 FY2025 Continued growth across medical cannabis businesses, with net revenue increasing year-over-year by 16% in Canada and 12% in international markets   Further improved balance sheet with early prepayment reducing senior secured term loan by US$100MM SMITHS FALLS, ON , Nov. 8, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC) today announces its financial results for the second quarter ended September 30, 2024 ("Q2 FY2025"). All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Canopy Growth Reports Second Quarter Fiscal Year 2025 Financial Results

Following Donald Trump's presidential election victory Tuesday, the cannabis sector took a sharp downturn.

Cannabis Stocks Collapse After Trump Win: Major Players See Double-Digit Declines At Wednesday's Close

Shares of cannabis companies fell Wednesday after a ballot measure that would have legalized recreational marijuana in Florida failed to pass.

Cannabis Stocks Plummet After Legalization Bid Fails in Florida

Global Tech Industries Group, Inc.

North Dakota and South Dakota also failed in their efforts to legalize cannabis for recreational use, while a medical measure passed in Nebraska.

Cannabis stocks crater as Florida fails to garner needed votes for adult use

Shares in cannabis stocks such as Trulieve Cannabis Corp. (CSE:TRUL), Curaleaf Hldgs Inc. (CSE:CURA, OTCQX:CURLF) and Verano Holdings Corp (CSE:VRNO, OTCQX:VRNOF) tanked after Florida rejected legalization of recreational marijuana. A ballot measure, known as Amendment 3, which would have allowed adults to possess up to three ounces of marijuana, failed to obtain the required 60% of support from voters yesterday.

Cannabis stocks tank as Florida votes against recreational marijuana

As the election approaches, Canadian cannabis stocks are capturing attention, especially with potential U.S. legalization developments on the horizon. The U.S. cannabis industry is booming, with projected growth reaching $41 billion by 2025. This massive market is appealing to Canadian companies seeking new revenue streams. Florida, in particular, is considering the legalization of recreational cannabis, which could unlock significant growth for Canadian cannabis companies with existing U.S. ties. If Florida joins the ranks of legal states, Canadian companies like Tilray, Canopy Growth, and Cronos Group could capitalize on this opportunity. These stocks are increasingly appealing to investors looking to benefit from potential changes in the U.S. market.

Top Canadian Cannabis Stocks to Track as U.S. Legalization Heats Up

Investors Heavily Search Canopy Growth Corporation (CGC): Here is What You Need to Know

SNDL Inc.

Marijuana stock investors are keeping a close eye on the sector. The reason for this is all that is occurring in the sector at this time. We have companies preparing to report earnings on top of the politics surrounding the promises of the presidential election. Politics can greatly impact trading depending on the circumstances. For instance, when a politician speaks in favor of legal cannabis, it has the potential to create a rise in trading.

3 Marijuana Stocks For Today's Trader

SMITHS FALLS, ON , Oct. 25, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC) will release its financial results for the second quarter fiscal year 2025 ended September 30, 2024 before financial markets open on November 8, 2024. Following the release of its second quarter fiscal year 2025 financial results, Canopy Growth will host an audio webcast with David Klein, CEO and Judy Hong, CFO on November 8, 2024 at 10 AM Eastern Time.

Canopy Growth to Report Second Quarter Fiscal 2025 Financial Results on November 8, 2024

Canopy Growth Corporation (CGC) closed the most recent trading day at $5.04, moving +1.2% from the previous trading session.

Canopy Growth Corporation (CGC) Increases Despite Market Slip: Here's What You Need to Know

SMITHS FALLS, ON , Oct. 17, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that it has made an early prepayment under its senior secured term loan (the "Term Loan") in an aggregate principal amount equal to US$100 million at a discounted price of US$97.5 million. This proactive move, which in addition to reducing the Company's leverage results in annualized interest expense savings of approximately US$14 million, underscores the Company's strong commitment to fiscal discipline and further strengthens its financial position as it continues to execute on its strategic priorities.

Canopy Growth Further Improves Balance Sheet with Early Prepayment to Reduce Term Loan by US$100 Million and Ensures Maturity Extension to at Least December 2026

Canopy Growth (CGC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here is What to Know Beyond Why Canopy Growth Corporation (CGC) is a Trending Stock

When looking for top marijuana stocks what would a person look for or do? Like all things, you need to do your homework. Some various sectors and companies make up the cannabis industry. Progress and success can mean better gains in the market. The cannabis industry as a whole has come a long way since it first began. Now with almost every state in the US having legal cannabis operations are growing for most companies. Also, places like Canada and certain parts of Europe have a legal cannabis industry as well.

Top Marijuana Stocks For Making Gains In The Sector

The latest trading day saw Canopy Growth Corporation (CGC) settling at $4.14, representing a -1.19% change from its previous close.

Here's Why Canopy Growth Corporation (CGC) Fell More Than Broader Market

Flora Growth Corp

Fort Lauderdale, Florida--(Newsfile Corp. - October 14, 2024) - Flora Growth Corp. (NASDAQ: FLGC) (FSE: 7301) ("Flora" or the "Company") is pleased to announce a distribution agreement with Canopy Growth Corp. (NASDAQ: CGC) for the distribution of Canopy's Storz & Bickel ("Storz") medical line of vaporizers in Australia through Flora's subsidiary, Australian Vaporizers. This agreement marks an expansion of Flora's footprint in the medical cannabis market in Australia.

Flora Growth Corp. Enters $94 million Australian Medical Cannabis Market with Canopy Growth Corp. Distribution Agreement for Storz & Bickel Vaporizers

In the closing of the recent trading day, Canopy Growth Corporation (CGC) stood at $4.03, denoting a -1.47% change from the preceding trading day.

News for Canopy Growth Stock (CGC)